AWS Health Innovation Podcast

Latest Episodes:

#105, Reducing Healthcare's $1 Trillion Admin Burden with AI, Abdel Mahmoud, Anterior Oct 23, 2024

Show notes

Anterior is on a mission to relieve doctors and nurses of administrative burden, starting with transforming the prior authorization process. In this episode of the AWS Health Innovation Podcast, Abdel Mahmoud, MD, CEO and Co-Founder of Anterior, shares how the company's generative AI technology is changing the game for healthcare professionals.

What inspired Abdel Mahmoud's vision for Anterior?
- Abdel shares his journey from immigrant roots to medical school, where he realized technology's potential to improve healthcare upstream. He recounts experiences at Facebook, UCL, and Google before co-founding Anterior to reduce healthcare's $1 trillion administrative burden.
How does Anterior bridge the gap between healthcare and tech?
- While healthcare faces resource constraints, clinicians show empathy despite challenges; tech startups prioritize rapid iteration. Anterior aligns provider and payer incentives through AI-powered clinical decisioning tools, contrasting the two worlds.
How does Anterior leverage large language models?
- Anterior ingests unstructured clinical data, using large language models to understand medical jargon, surface insights, and increase clinician productivity reviewing cases like prior authorizations. Rigorous evaluation pipelines ensure model accuracy.
What has Anterior learned about designing for seamless user experiences?
- A key learning has been the importance of streamlined user experiences, enabling clinicians to quickly validate AI recommendations with minimal effort, even on mobile devices.
What was Anterior's fundraising journey, and what advice does Abdel offer founders?
- The path involved an accelerator, seed round from Sequoia, then Series A from NEA to scale. Advice includes joining accelerators, demonstrating traction, articulating an ambitious vision, and prioritizing strategic thinking as CEO.

To learn more about Anterior's mission to reduce the administrative burden in healthcare, visit their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#104, Decoding the Immune System with AI, Adam Laing from IMU Biosciences Oct 16, 2024

Show notes

On today's episode we learn all about the immune system with Adam Laing, Co-founder & Chief Scientific Officer of IMU Biosciences, as he joins Alex Merwin, Head of Growth for Healthcare & Life Science Startups at AWS, on the AWS Health Innovation Podcast. IMU Biosciences is transforming our understanding of the immune system by leveraging AI-powered immune profiling to create unprecedented insights into health and disease, to advance precision medicine through collaborations with leading pharma, research organizations, and academic institutions.

1. How is IMU Biosciences unlocking immune insights?

IMU Biosciences' pioneering technology measures 80 million data points across 2,000 immune cell subsets, from a small blood sample, providing unprecedented resolution into an individual's immune profile. This enables precision medicine approaches across disease areas like cancer, autoimmunity, and cell therapy.

2. What is the potential of predictive immune profiling?

By deeply characterizing immune systems, IMU aims to predict disease progression and treatment responses. Their machine learning analytics identify immune signatures that can stratify patients based on how effectively they will respond to therapies.

3. How does IMU Biosciences foster a collaborative culture?

With a team spanning immunology, data science, engineering, and operations, IMU fosters a collaborative culture focused on solving complex problems. Their network and reputation helped secure early industry partnerships.

4. What is IMU Biosciences' vision for scaling precision immunology?

After demonstrating their technology's potential during COVID-19 research, IMU raised a Series A to commercialize and build a predictive immune data platform. Their long-term vision is enabling preventative screening for disease risk.

5. How does IMU Biosciences leverage advances in flow cytometry?

IMU leverages advances in flow cytometry instrumentation, labeling 75 markers to phenotype cells at unprecedented resolution. Robust processes ensure scalability by accounting for technical variability across samples.

Learn more about IMU Biosciences here to explore their pioneering work in unlocking the complexity of the immune system and advancing precision medicine.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#103, Revolutionizing Surgery with Physical AI, Gabriel Jones from Proprio Oct 08, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, host Eric Zimmerman, Principal Healthcare & Life Sciences BD at AWS, sits down with Gabriel Jones, CEO of Proprio, a company revolutionizing surgery through AI, computer vision, and augmented reality. Proprio's mission is to enhance surgical precision and decision-making with real-time, interactive 3D visualization and simulations.

1. How is Proprio transforming the surgical landscape with AI?

Gabriel Jones shares insights on how AI and advanced imaging will revolutionize surgery, enabling real-time data visualization and predictive analytics. This aligns with Proprio's mission to enhance surgical precision through intelligent technology.

2. What was the key to Proprio's innovative approach?

The founding team's diverse expertise in neurosurgery, computer vision, and sensor systems allowed Proprio to converge disparate data sources into a novel imaging modality. This interdisciplinary approach drives innovation in surgical visualization.

3. How did Proprio navigate the product development process?

While Proprio's core thesis endures, the company embraced an iterative product development cycle, learning that initial concepts require refinement through user feedback and prototyping. Constant adaptation is key in deep tech.

4. What factors have enabled Proprio's "physical AI" approach?

Recent breakthroughs in AI, sensors, and data integration have created an opportune environment for Proprio's "physical AI" approach of bridging the physical and digital realms in healthcare. Timing is crucial for deep tech success.

5. How does Proprio envision democratizing healthcare innovation?

Proprio envisions enabling clinicians to invent novel products and services powered by its data platform, while pressuring incumbents to accelerate innovation. This could democratize healthcare solutions development.

6. What is Proprio's focus for talent acquisition?

As an AI company focused on computer vision, robotics and engineering, Proprio is actively hiring top talent to drive partnerships and growth in its transformative vision for surgery and healthcare.

Learn more about Proprio and their innovative surgical technology on their website.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#102, Decoding Human Biology with Single-Cell Insights, with Lindsay Edwards from Relation Sep 24, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, host Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, sits down with Lindsay Edwards, CTO and President of Platform at Relation, a biotech company leveraging single-cell multi-omics, machine learning, and clinical insights to develop transformational medicines.

1. What is Relation's unconventional approach to drug discovery?

Lindsay Edwards, a former musician turned drug hunter, embodies Relation's bold mission to transform drug discovery through multidisciplinary expertise bridging biology, data science, and creative intuition.
Relation harnesses human genetic insights and single-cell data to pinpoint superior drug targets, addressing a critical bottleneck in pharmaceutical R&D.

2. How does Relation integrate lab experiments and machine learning?

Relation's "Lab-in-the-Loop" approach tightly integrates wet lab experiments with machine learning, iteratively refining models that map genetic variation to disease mechanisms.
Interdisciplinary collaboration between biologists, data scientists, and computational experts catalyzes this symbiosis of lab and AI.

3. How does Relation's initial focus in developing precision medicines for osteoporosis open opportunities in other therapuetic areas?

By studying osteoblasts and genetic determinants of bone density, Relation aims to develop anabolic therapies driving new bone growth, addressing the large unmet need in osteoporosis with precision medicine.
Their traction in osteoporosis shows how Relation can apply biological signals to improve machine learning modeling, uncover novel therapeutic targets.

To learn more about Relation and their transformative approach to drug discovery, visit their website: https://www.relationrx.com/

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#101, Improving Lab Workflows with Robotics and AI, Mostafa ElSayed of Automata Sep 17, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, sits down with Mostafa ElSayed, Co-founder and CEO of Automata, a company revolutionizing the way scientists work in labs by providing a full-stack solution for lab automation.

How does Automata's LINQ platform streamline drug discovery workflows?
- Automata's LINQ platform integrates robotics, instruments, and cloud software, addressing inefficiencies in life sciences labs. As a modular "work cell", it captures structured data to accelerate collaboration and time-to-market for therapeutics.
What inspired Mostafa ElSayed's vision for Automata?
- Mostafa ElSayed's background in architecture sparked an interest in robotics, leading him to co-found Automata and pioneer a full-stack lab automation solution. His vision fuses design principles with cutting-edge technology to transform drug R&D.
What does ElSayed envision for the future of drug discovery?
- ElSayed envisions AI-driven drug discovery becoming the norm within a decade, with a shift towards computational "in silico" approaches over lab-based "in vitro" methods. Robust data and transparency will increase confidence in clinical candidates.
How does Automata balance product vision with user feedback?
- Automata balances product vision with user feedback, investing heavily in hardware modularity, software UX/UI, and developer experience. Design drives customer success by optimizing different user journeys through an experience lens.

To learn more about Automata and their innovative lab automation solutions, visit https://automata.tech/.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#100, Enabling Personalized Medicine with Virtual Biopsies, Rajarshi Banerjee from Perspectum Aug 30, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, Amrita Sarkar, Principal Healthcare and Life Sciences Startups Business Development Manager at Amazon Web Services, sits down with Rajarshi Banerjee, aka 'Banjo', the CEO of Perspectum, a company revolutionizing the way we diagnose and monitor chronic diseases. Perspectum's medical imaging software applies artificial intelligence to enhance MRI scans, providing greater precision in measuring organ inflammation and enabling non-invasive "virtual biopsies" to avoid complications associated with invasive approaches.

How did Perspectum's innovative approach to medical imaging originate?
- During his PhD research on cardiac MRI at Oxford, Banjo developed non-invasive tissue characterization methods. This led to creating Liver MultiScan, addressing the massive need for non-invasive liver disease diagnosis.
What is Perspectum's vision for personalized medicine, and how are they working towards it?
- Perspectum strategically expanded beyond liver disease to conditions like long COVID, diabetes, and cancer, aligning with their vision for personalized medicine. They collaborate transparently across ethnicities and geographies to address healthcare inequities.
How has Perspectum's user-friendly approach contributed to the adoption of their solutions?
- Perspectum designed FDA-cleared reports to effectively communicate liver disease status, replacing invasive biopsies with non-invasive LiverMultiScan in early-stage clinical trials. Their solutions influenced regulatory decisions and diagnostic criteria.
How does Perspectum prioritize data security and privacy in their solutions?
- Meeting stringent cybersecurity standards from early collaborations with U.S. military hospitals, Perspectum emphasizes standardizing and signposting cybersecurity requirements for safe AI healthcare delivery. Their software augments physicians' capabilities while ensuring patient communication.
What insights does Banjo share about fostering an entrepreneurial mindset and driving innovation?
- Inspired by his mother's pioneering work in computing, Banjo encourages entrepreneurs to embrace making their own mistakes. Perspectum envisions improving patient outcomes through safer procedures, faster diagnoses, and multi-organ disease analysis capabilities.
In what conditions has Perspectum's non-invasive AI powered scans been shown to facilitate safer assessment and monitoring?

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#99, Soothing Cries & Saving Lives with Innovative Baby Tech, Dr. Harvey Karp from Happiest Baby Aug 20, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare and Life Sciences Startups at AWS, interviews Dr. Harvey Karp, Founder and CEO of Happiest Baby, the company behind the SNOO Smart Sleeper - a robotic bassinet designed to calm fussing infants and establish healthy sleep patterns.

How did Dr. Karp's experience as a pediatrician lead to the creation of the SNOO?

As a pediatrician and child development expert, Dr. Karp witnessed firsthand the challenges parents face with excessive infant crying and sleep deprivation. His quest to soothe colic and promote healthy sleep led him to develop the SNOO, a smart bassinet that mimics the womb environment by responding to fussing with gentle rocking and soothing sounds.

What makes the SNOO a groundbreaking product in the healthcare industry?

In a pioneering move, the SNOO bassinet received FDA de novo approval in March 2023 as a medical device, making it the first smart crib to achieve this status. This clearance paves the way for insurance coverage and rental programs, aligning with Karp's vision of making this technology accessible to families through employer benefits and other initiatives.

What challenges did Dr. Karp face in bringing the SNOO to market?

Transforming the SNOO concept into a viable product took over two years of engineering challenges to create a smooth, quiet rocking motion. Despite funding obstacles, Karp leveraged his existing brand and persevered, demonstrating the entrepreneurial perseverance required to bring innovative healthcare solutions to market.

How does the SNOO challenge traditional beliefs about infant care?

The SNOO raises intriguing questions about optimal infant care practices. While conventional wisdom suggests leaving babies alone is best for brain development, Karp theorizes that rocking and shushing may be neurological needs beyond just soothing techniques, challenging traditional beliefs about infant care.

How has the SNOO been received by customers and healthcare professionals?

With a remarkable net promoter score of 89 and use in 160 hospitals, the SNOO demonstrates extremely high customer satisfaction by reducing nurse workloads. Karp's focus on solving real family pain points is driving strong product-market fit, as evidenced by the positive reception from both parents and healthcare professionals.

To learn more about Happiest Baby and the SNOO Smart Sleeper, visit http://www.happiestbaby.com/.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#98, Advancing Adaptive Clinical Trials with Causal ML, with Raviv Pryluk from PhaseV Aug 13, 2024

Show notes

In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at Amazon Web Services, sits down with Raviv Pryluk, CEO and Co-Founder of PhaseV, a company leveraging cutting-edge technologies like reinforcement learning and causal machine learning to revolutionize clinical trial design and execution.

1. How did Raviv and his co-founder identify the clinical trials space as ripe for innovation?

Raviv shares the extensive research and criteria-driven process he undertook with co-founder Elad to identify the clinical trials space as ripe for innovation. They sought an area with major positive impact potential that leveraged their expertise in machine learning, neuroscience, and engineering.

2. What innovative technologies does PhaseV employ to transform clinical trials?

PhaseV's platforms harness cutting-edge technologies like reinforcement learning and causal ML to enable adaptive trial designs and advanced data analysis. This allows more efficient, ethical trials with faster detection of subgroups responding differently to treatments.

3. How does PhaseV's causal ML platform extract insights from complex biological data?

PhaseV's causal ML platform can analyze intricate biological mechanisms and multi-endpoint trials to identify true causal relationships, not just correlations. This surfaces actionable insights into why certain patient subgroups respond better to specific drugs.

4. How does PhaseV aim to accelerate drug development timelines?

By leveraging machine learning for surrogate endpoints and virtual head-to-head comparisons in Phase 2, PhaseV aims to predict trial outcomes faster. This could dramatically reduce the 10+ year, $3B+ timeline for new drug approvals.

5. How is PhaseV positioned to capitalize on regulatory shifts post-COVID?

The pandemic prompted increasing regulatory flexibility and digitization in clinical trials. PhaseV is well-positioned to capitalize on this evolving landscape and usher in a new era of precision medicine through innovative trial methodologies.

6. How does PhaseV build its multidisciplinary team?

Raviv discusses PhaseV's strategic hiring approach, carefully assembling a diverse team spanning software, data science, medicine, and biology. Maintaining an "adaptive" mindset allows continuous reevaluation based on new data.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#97, Preventing Adverse Drug Events at Scale, with Avishai Ben-Tovim from MDI Health Aug 06, 2024

Show notes

Medication-related problems are a massive burden on healthcare systems, leading to adverse events, suboptimal treatments, and skyrocketing costs. MDI Health has developed an AI-driven pharmacology platform that autonomously optimizes personal medication regimens by analyzing thousands of pharmacological and patient parameters. Joining us today is Avishai Ben-Tovim, CEO and Co-Founder of MDI Health, to share how their powerful AI identifies high-risk patients, provides clinicians with evidence-based recommendations to reduce risks in real-time, and helps payers and providers execute those recommendations - ultimately reducing total care costs while improving quality.

What is MDI Health's approach to Medication Therapy Mastery?
- MDI Health's AI platform analyzes thousands of pharmacological and patient parameters to optimize medication regimens across populations. It identifies high-risk patients for adverse drug events and provides real-time recommendations to reduce risks and lower care costs.
How did MDI Health overcome barriers in the healthcare industry?
- Avishai discusses how MDI Health conducted clinical studies, secured early customers through resourcefulness, and provided clinical validation to convince chief medical officers of their value proposition.
What is the concept of a Collaborative AI Co-Pilot?
- MDI Health's evidence-based algorithm maps pharmacological rules, trained by comparing to expert analysis on real cases. It complements existing systems by surfacing insights and suggested actions clinicians often miss.
How does MDI Health aim to align healthcare incentives?
- Avishai aims to enable data exchange and aligned incentives between health plans and providers. MDI Health's solution improves efficiency and holistic patient care impact for all stakeholders.
What is MDI Health's approach to building a mission-driven culture?
- From the start, MDI Health prioritized building a strong organizational culture focused on the mission. They foster ownership, openness, learning, and retaining employees who deeply care.
How does MDI Health educate the market on their solution?
- MDI Health leverages conferences, relationships, and continuous improvement to educate the market on their proven AI technology and value proposition for medication optimization.

Learn more about MDI Health here to understand how their AI-driven pharmacology platform can optimize medication regimens and reduce healthcare costs.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

#96, Unlocking Precision Health with Oculomics, with Carlos Ciller from Ikerian Jul 30, 2024

Show notes

Accelerating medical decision-making with AI is the mission of Ikerian, a Swiss software company enabling healthcare teams to harmonize and analyze data at scale. In this episode of the AWS Health Innovation Podcast, Alex Merwin, Head of Growth for Healthcare and Life Science Startups at AWS, is joined by Carlos Ciller, CEO and co-founder of Ikerian, to discuss their innovative platform and approach.

Carlos shares insights into Ikerian's journey, from its origins as a retinal imaging AI startup called RetinAI, to evolving into a comprehensive data platform serving pharmaceutical companies, physicians, and researchers across therapeutic areas. The discussion explores how Ikerian is empowering stakeholders to detect diseases sooner through biomarker identification, optimize treatment decisions with curated insights, expedite clinical collaboration through efficient workflows, and accelerate drug development by aggregating learnings. Carlos also discusses the key components of their scalable cloud platform, their focus on user experience and education, and the entrepreneurial resilience required to bring such an ambitious vision to reality.

Founder's Entrepreneurial Journey
- Carlos Ciller shares his background, from studying in Barcelona to co-founding Icarian in Switzerland. He discusses the resilience and commitment required as an entrepreneur, learning from failures, and the importance of time management after becoming a father.
Oculomics: Unlocking Systemic Health
- The eye provides a window into systemic diseases, a field known as "oculomics." Retinal scanning offers a low-cost, automated diagnostic modality compared to alternatives like MRI, enabling early disease detection and optimized treatment decisions.
Diverse Customer Needs, Unified Solution
- Ikerian caters to pharmaceutical companies (AI, medical, market access teams) and physicians, offering AI analysis, clinical studies, patient identification, decision support, and patient engagement through a unified, cloud-based platform.
Scalable Cloud Infrastructure Enabler
- Leveraging Amazon's scalable cloud infrastructure, Icarian's platform can dynamically scale based on customer needs, comprising image/data management, task processing, clinical viewer, and modular AI components.
User-Centric Design for Adoption
- Recognizing the importance of user experience and education in healthcare, Icarian focuses on user-centric design to drive platform adoption among pharmaceutical companies and physicians.

Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.

Please take a moment and let us know what you think of the podcast, access our feedback survey here.

To learn more about Ikerian and their innovative platform, visit ikerian.com.

Our TOPPODCAST Picks

Follow Us

Stay Connected

AWS Health Innovation Podcast

Related Podcasts

Links

Stay Connected